Amphastar Pharmaceuticals
AMPH
255 hedge funds and large institutions have $1.47B invested in Amphastar Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 89 increasing their positions, 92 reducing their positions, and 28 closing their positions.
46% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 28
4% more funds holding
Funds holding: 245 → 255 (+10)
5% more call options, than puts
Call options by funds: $1.25M | Put options by funds: $1.19M
0.43% more ownership
Funds ownership: 65.07% → 65.5% (+0.43%)
3% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 92
18% less capital invested
Capital invested by funds: $1.8B → $1.47B (-$332M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
+$10M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$9.36M |
| 3 |
Bessemer Group
Woodbridge,
New Jersey
|
+$8.06M |
| 4 |
Renaissance Technologies
New York
|
+$6.03M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$11M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$8.19M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$5.75M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$4.15M |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
-$3.69M |
AMPH Hedge Fund Activity: Q3 2023 in Review
255 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q3 2023, worth a combined $1.47B — down 18% from $1.8B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new AMPH positions and 28 closed out — a net gain of 13 holders — while 89 added to existing stakes and 92 trimmed.
The largest buyer was Voloridge Investment Management, adding an estimated $10M. The largest seller was Granite Investment Partners, cutting an estimated $11M.
- 255 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q3 2023, up from 245 in Q2 2023.
- Funds reported $1.47B of Amphastar Pharmaceuticals stock for Q3 2023, down 18% quarter-over-quarter.
- 41 funds opened new Amphastar Pharmaceuticals positions in Q3 2023 and 28 closed out, a net change of +13 holders.
- The largest Amphastar Pharmaceuticals buyer in Q3 2023 was Voloridge Investment Management, an estimated $10M added.
- The largest Amphastar Pharmaceuticals seller in Q3 2023 was Granite Investment Partners, an estimated $11M sold.
Based on aggregated 13F filings for Q3 2023.